Groundbreaking Progress in GvHD Treatment: Tr1X Successfully Doses First Patient in TRX103 Trial

Tr1X logo

In an exciting development for autoimmune and inflammatory disorders, Tr1X, Inc. has announced the successful dosing of the first patient in its TRX103-01 proof-of-concept trial. This trial is a significant step forward in the fight against Graft versus Host Disease (GvHD), a serious condition affecting patients undergoing mismatched hematopoietic stem cell transplantation (HSCT). TRX103 represents […]